Pronounced reduction of postprandial glucagon by lixisenatide: A meta-analysis of randomized clinical trials

Diabetes, Obesity and Metabolism

Volumn 16, Issue 9, 2014, Pages 861-868

  Ahren B ^a   Gautier, J F ^b   Berria, R ^c   Stager, W ^c   Aronson, R ^d   Bailey, C J ^e  

^a LUND UNIVERSITY   (Sweden)

^b HÔPITAL LARIBOISIÈRE   (France)

^c SANOFI   (France)

^d LMC DIABETES AND ENDOCRINOLOGY   (Canada)

^e ASTON UNIVERSITY   (United Kingdom)

Author keywords

Diabetes mellitus; GLP 1; Insulin secretion

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; GLUCAGON; INSULIN; LIXISENATIDE; METFORMIN; ORAL ANTIDIABETIC AGENT; SULFONYLUREA DERIVATIVE; ANTIDIABETIC AGENT; GLUCAGON LIKE PEPTIDE 1; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; PEPTIDE; ZP10A PEPTIDE;

ADD ON THERAPY; ARTICLE; CONTROLLED CLINICAL TRIAL (TOPIC); DIABETIC PATIENT; DRUG MECHANISM; GASTROINTESTINAL SYMPTOM; GLUCAGON BLOOD LEVEL; GLUCAGON RELEASE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN RELEASE; INSULIN RESPONSE; META ANALYSIS; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS FUNCTION; PHASE 3 CLINICAL TRIAL (TOPIC); POSTPRANDIAL STATE; RANDOMIZED CONTROLLED TRIAL (TOPIC); STOMACH EMPTYING; AGONISTS; BLOOD; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; METABOLISM; SECRETION (PROCESS);

BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; GASTRIC EMPTYING; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; PEPTIDES; POSTPRANDIAL PERIOD; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84905739727     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12290     Document Type: Article

References (40)

1. DeFronzo RA. Lilly lecture 1987. The triumvirate: beta-cell, muscle, liver. A collusion responsible for NIDDM. Diabetes 1988; 37: 667-687.
2. Muller WA, Faloona GR, Aguilar-Parada E, Unger RH. Abnormal alpha-cell function in diabetes. Response to carbohydrate and protein ingestion. N Engl J Med 1970; 283: 109-115.
3. Toft-Nielsen MB, Damholt MB, Madsbad S et al. Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. J Clin Endocrinol Metab 2001; 86: 3717-3723.
4. Unger RH. Glucagon physiology and pathophysiology. N Engl J Med 1971; 285: 443-449.
5. Frank JW, Camilleri M, Thomforde GM, Dinneen SF, Rizza RA. Effects of glucagon on postprandial carbohydrate metabolism in nondiabetic humans. Metabolism 1998; 47: 7-12.
6. Meier JJ, Kjems LL, Veldhuis JD, Lefebvre P, Butler PC. Postprandial suppression of glucagon secretion depends on intact pulsatile insulin secretion: further evidence for the intraislet insulin hypothesis. Diabetes 2006; 55: 1051-1056.
7. Shah P, Vella A, Basu A, Basu R, Schwenk WF, Rizza RA. Lack of suppression of glucagon contributes to postprandial hyperglycemia in subjects with type 2 diabetes mellitus. J Clin Endocrinol Metab 2000; 85: 4053-4059.
8. Ahren B. GLP-1 for type 2 diabetes. Exp Cell Res 2011; 317: 1239-1245.
9. Ahren B, Larsson H, Holst JJ. Effects of glucagon-like peptide-1 on islet function and insulin sensitivity in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1997; 82: 473-478.
10. Fineman MS, Cirincione BB, Maggs D, Diamant M. GLP-1 based therapies: differential effects on fasting and postprandial glucose. Diabetes Obes Metab 2012; 14: 675-688.
11. Dunning BE, Foley JE, Ahren B. Alpha cell function in health and disease: influence of glucagon-like peptide-1. Diabetologia 2005; 48: 1700-1713.
12. Nauck MA, Niedereichholz U, Ettler R et al. Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. Am J Physiol 1997; 273: E981-E988.
13. Hare KJ, Vilsboll T, Asmar M, Deacon CF, Knop FK, Holst JJ. The glucagonostatic and insulinotropic effects of glucagon-like peptide 1 contribute equally to its glucose-lowering action. Diabetes 2010; 59: 1765-1770.
14. Meier JJ. GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nat Rev Endocrinol 2012; 8: 728-742.
15. Kapitza C, Forst T, Coester HV, Poitiers F, Ruus P, Hincelin-Mery A. Pharmacodynamic characteristics of lixisenatide once daily versus liraglutide once daily in patients with type 2 diabetes insufficiently controlled on metformin. Diabetes Obes Metab 2013; 15: 642-649.
16. Nauck MA, Kemmeries G, Holst JJ, Meier JJ. Rapid tachyphylaxis of the glucagon-like peptide 1-induced deceleration of gastric emptying in humans. Diabetes 2011; 60: 1561-1565.
17. Fonseca VA, Alvarado-Ruiz R, Raccah D et al. Efficacy and safety of the once-daily GLP-1 receptor agonist lixisenatide in monotherapy: a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes (GetGoal-Mono). Diabetes Care 2012; 35: 1225-1231.
18. Ahren B, Leguizamo Dimas A, Miossec P, Saubadu S, Aronson R. Efficacy and safety of lixisenatide once-daily morning or evening injections in type 2 diabetes inadequately controlled on metformin (GetGoal-M). Diabetes Care 2013; 36: 2543-2550.
19. Pinget M, Goldenberg R, Niemoeller E, Muehlen-Bartmer I, Guo H, Aronson R. Efficacy and safety of lixisenatide once daily versus placebo in type 2 diabetes insufficiently controlled on pioglitazone (GetGoal-P). Diabetes Obes Metab 2013; 15: 1000-1007.
20. Rosenstock J, Raccah D, Koranyi L et al. Efficacy and safety of lixisenatide once daily versus exenatide twice daily in type 2 diabetes inadequately controlled on metformin: a 24-week, randomized, open-label, active-controlled study (GetGoal-X). Diabetes Care 2013; 36: 2945-2951.
21. Ratner R, Hanefeld M, Shamanna P et al. Efficacy and safety of lixisenatide once daily versus placebo in patients with T2DM insufficiently controlled on sulfonylurea+metformin (GetGoal-S). Diabetologia 2011; 54: 1-542(Abstract 785).
22. Riddle MC, Aronson R, Home P et al. Adding once-daily lixisenatide for type 2 diabetes inadequately controlled by established basal insulin: a 24-week, randomized, placebo-controlled comparison (GetGoal-L). Diabetes Care 2013; 36: 2489-2496.
23. Riddle MC, Forst T, Aronson R et al. Adding once-daily lixisenatide for type 2 diabetes inadequately controlled with newly initiated and continuously titrated basal insulin glargine: a 24-week, randomized, placebo-controlled study (GetGoal-Duo 1). Diabetes Care 2013; 36: 2497-2503.
24. Seino Y, Min KW, Niemoeller E, Takami A, Investigators EG-LAS. Randomized, double-blind, placebo-controlled trial of the once-daily GLP-1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea (GetGoal-L-Asia). Diabetes Obes Metab 2012; 14: 910-917.
25. Unger RH, Orci L. The essential role of glucagon in the pathogenesis of diabetes mellitus. Lancet 1975; 1: 14-16.
26. Drucker DJ. The biology of incretin hormones. Cell Metab 2006; 3: 153-165.
27. Marathe CS, Rayner CK, Jones KL, Horowitz M. Effects of GLP-1 and incretin-based therapies on gastrointestinal motor function. Exp Diabetes Res 2011; 2011: 279530.
28. Shah P, Basu A, Basu R, Rizza R. Impact of lack of suppression of glucagon on glucose tolerance in humans. Am J Physiol 1999; 277: 283-290.
29. Lorenz M, Pfeiffer C, Steinstrasser A et al. Effects of lixisenatide once daily on gastric emptying in type 2 diabetes - relationship to postprandial glycemia. Regul Pept 2013; 185C: 1-8.
30. D'Alessio D. The role of dysregulated glucagon secretion in type 2 diabetes. Diabetes Obes Metab 2011; 13(Suppl. 1): 126-132.
31. Cherrington AD, Chiasson JL, Liljenquist JE, Jennings AS, Keller U, Lacy WW. The role of insulin and glucagon in the regulation of basal glucose production in the postabsorptive dog. J Clin Invest 1976; 58: 1407-1418.
32. Hancock AS, Du A, Liu J, Miller M, May CL. Glucagon deficiency reduces hepatic glucose production and improves glucose tolerance in adult mice. Mol Endocrinol 2010; 24: 1605-1614.
33. Kim WD, Lee YH, Kim MH et al. Human monoclonal antibodies against glucagon receptor improve glucose homeostasis by suppression of hepatic glucose output in diet-induced obese mice. PLoS One 2012; 7: e50954.
34. Liljenquist JE, Mueller GL, Cherrington AD et al. Evidence for an important role of glucagon in the regulation of hepatic glucose production in normal man. J Clin Invest 1977; 59: 369-374.
35. Rivera N, Everett-Grueter CA, Edgerton DS et al. A novel glucagon receptor antagonist, NNC 25-0926, blunts hepatic glucose production in the conscious dog. J Pharmacol Exp Ther 2007; 321: 743-752.
36. Sorensen H, Brand CL, Neschen S et al. Immunoneutralization of endogenous glucagon reduces hepatic glucose output and improves long-term glycemic control in diabetic ob/ob mice. Diabetes 2006; 55: 2843-2848.
37. Heller RS, Kieffer TJ, Habener JF. Insulinotropic glucagon-like peptide I receptor expression in glucagon-producing alpha-cells of the rat endocrine pancreas. Diabetes 1997; 46: 785-791.
38. Plamboeck A, Veedfald S, Deacon CF et al. The effect of exogenous GLP-1 on food intake is lost in male truncally vagotomized subjects with pyloroplasty. Am J Physiol Gastrointest Liver Physiol 2013; 304: G1117-G1127.
39. Drucker DJ, Philippe J, Mojsov S, Chick WL, Habener JF. Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line. Proc Natl Acad Sci U S A 1987; 84: 3434-3438.
40. Fehmann HC, Habener JF. Functional receptors for the insulinotropic hormone glucagon-like peptide-I(7-37) on a somatostatin secreting cell line. FEBS Lett 1991; 279: 335-340.